HSRT and IMRT Chemoradiotherapy for Newly Diagnosed GBM (HSCK-010)
The Combination of Hypofractionated Stereotactic Radiotherapy and Chemoradiotherapy Using Intensity-Modulated Radiotherapy for Newly Diagnosed Glioblastoma Multiforme: A Prospective, Single-Center, Single-Arm Phase II Clinical Trial
Sponsor: Huashan Hospital
Listed as NCT04547621, this PHASE1/PHASE2 trial focuses on Glioma, Malignant and remains ongoing. Sponsored by Huashan Hospital, it has been updated 5 times since 2020, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE1/PHASE2
Status: Unknown Status → Unknown · Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Feb 2024 — Jul 2024 [monthly]
Unknown Status PHASE1_PHASE2
Status: Active Not Recruiting → Unknown Status
-
Jan 2021 — Feb 2024 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Oct 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE1_PHASE2
First recorded
Sep 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Huashan Hospital
For direct contact, visit the study record on ClinicalTrials.gov .